Clinical Oncology Next Generation Sequencing (NGS) Market to 2027 - Global Analysis and Forecasts By Technology (Whole Exome Sequencing, Whole Genome Sequencing and Targeted Sequencing & Resequencing); Workflow (NGS Data Analysis, NGS Pre-Sequencing and NGS Sequencing); Application (Companion Diagnostics, Screening and Other Applications); End User (Hospitals & Clinics and Laboratories), and Geography
Report Code: TIPRE00007163 No. of Pages: 150 Category: Biotechnology Status: Upcoming
MARKET INTRODUCTION
Next-generation sequencing is a technique that helps in conducting various reactions simultaneously, through which DNA or RNA can be sequenced. During recent years, NGS has revolutionized cancer genetics by providing access to genomic and transcriptomic data to the researchers in this field. Most of the oncologists in developed nations such as the United States use the technique of NGS to provide better treatment for their patients.
MARKET DYNAMICS
The clinical oncology next-generation sequencing (NGS) market is anticipated to grow in the forecast, owing to the rise in the prevalence of cancer, coupled with technological advancements in the field of next-generation sequencing. In addition, an increase in the preference for NGS than single-gene testing is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Clinical Oncology Next Generation Sequencing (NGS) Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of clinical oncology next generation sequencing (NGS) market with detailed market segmentation by technology, workflow, application, end user, and geography. The clinical oncology next generation sequencing (NGS) market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading clinical oncology next generation sequencing (NGS) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The clinical oncology next generation sequencing (NGS) market is segmented on the basis of technology, workflow, application, and end user. Based on technology the market is segmented as, whole exome sequencing, whole genome sequencing and targeted sequencing & resequencing. On the basis of workflow, the market is segmented as, NGS data analysis, NGS pre-sequencing and NGS sequencing. The clinical oncology next generation sequencing (NGS) market is categorized based on application such as companion diagnostics, screening and other applications. Similarly, on the basis of end user, the market is segmented as, hospitals & clinics and laboratories.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the clinical oncology next generation sequencing (NGS) market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting clinical oncology next generation sequencing (NGS) market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the clinical oncology next generation sequencing (NGS) market in these regions.
The report covers key developments in the clinical oncology next generation sequencing (NGS) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from clinical oncology next generation sequencing (NGS) market are anticipated to have lucrative growth opportunities in the future with the rising demand for clinical oncology next generation sequencing (NGS) market in the global market. Below mentioned is the list of few companies engaged in the clinical oncology next generation sequencing (NGS) market.
The report also includes the profiles of key clinical oncology next generation sequencing (NGS) market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Next-generation sequencing is a technique that helps in conducting various reactions simultaneously, through which DNA or RNA can be sequenced. During recent years, NGS has revolutionized cancer genetics by providing access to genomic and transcriptomic data to the researchers in this field. Most of the oncologists in developed nations such as the United States use the technique of NGS to provide better treatment for their patients.
MARKET DYNAMICS
The clinical oncology next-generation sequencing (NGS) market is anticipated to grow in the forecast, owing to the rise in the prevalence of cancer, coupled with technological advancements in the field of next-generation sequencing. In addition, an increase in the preference for NGS than single-gene testing is expected to offer significant growth opportunities in the market during the forecast period.
MARKET SCOPE
The "Clinical Oncology Next Generation Sequencing (NGS) Market Analysis to 2027" is a specialized and in-depth study of the biotechnology industry with a special focus on the global market trend analysis. The report aims to provide an overview of clinical oncology next generation sequencing (NGS) market with detailed market segmentation by technology, workflow, application, end user, and geography. The clinical oncology next generation sequencing (NGS) market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading clinical oncology next generation sequencing (NGS) market players and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The clinical oncology next generation sequencing (NGS) market is segmented on the basis of technology, workflow, application, and end user. Based on technology the market is segmented as, whole exome sequencing, whole genome sequencing and targeted sequencing & resequencing. On the basis of workflow, the market is segmented as, NGS data analysis, NGS pre-sequencing and NGS sequencing. The clinical oncology next generation sequencing (NGS) market is categorized based on application such as companion diagnostics, screening and other applications. Similarly, on the basis of end user, the market is segmented as, hospitals & clinics and laboratories.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the clinical oncology next generation sequencing (NGS) market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The clinical oncology next generation sequencing (NGS) market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting clinical oncology next generation sequencing (NGS) market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the clinical oncology next generation sequencing (NGS) market in these regions.
The report covers key developments in the clinical oncology next generation sequencing (NGS) market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from clinical oncology next generation sequencing (NGS) market are anticipated to have lucrative growth opportunities in the future with the rising demand for clinical oncology next generation sequencing (NGS) market in the global market. Below mentioned is the list of few companies engaged in the clinical oncology next generation sequencing (NGS) market.
The report also includes the profiles of key clinical oncology next generation sequencing (NGS) market companies along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Agilent Technologies, Inc.
- Caris Life Sciences
- F. Hoffmann-La Roche Ltd
- FOUNDATION MEDICINE, INC.
- Illumina, Inc.
- Myriad Genetics, Inc.
- Oxford Nanopore Technologies
- Paradigm Diagnostics, Inc.
- QIAGEN
- Thermo Fisher Scientific Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market - By Technology
1.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market - By Workflow
1.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market - By Application
1.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market - By End User
1.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - GLOBAL MARKET ANALYSIS
6.1. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET OVERVIEW
6.2. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. WHOLE EXOME SEQUENCING
7.3.1. Overview
7.3.2. Whole Exome Sequencing Market Forecast and Analysis
7.4. WHOLE GENOME SEQUENCING
7.4.1. Overview
7.4.2. Whole Genome Sequencing Market Forecast and Analysis
7.5. TARGETED SEQUENCING & RESEQUENCING
7.5.1. Overview
7.5.2. Targeted Sequencing & Resequencing Market Forecast and Analysis
8. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - WORKFLOW
8.1. OVERVIEW
8.2. WORKFLOW MARKET FORECASTS AND ANALYSIS
8.3. NGS DATA ANALYSIS
8.3.1. Overview
8.3.2. NGS Data Analysis Market Forecast and Analysis
8.4. NGS PRE-SEQUENCING
8.4.1. Overview
8.4.2. NGS Pre-Sequencing Market Forecast and Analysis
8.5. NGS SEQUENCING
8.5.1. Overview
8.5.2. NGS Sequencing Market Forecast and Analysis
9. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. COMPANION DIAGNOSTICS
9.3.1. Overview
9.3.2. Companion Diagnostics Market Forecast and Analysis
9.4. SCREENING
9.4.1. Overview
9.4.2. Screening Market Forecast and Analysis
9.4.3. Inherited Cancer Market
9.4.3.1. Overview
9.4.3.2. Inherited Cancer Market Forecast and Analysis
9.4.4. Sporadic Cancer Market
9.4.4.1. Overview
9.4.4.2. Sporadic Cancer Market Forecast and Analysis
9.5. OTHER APPLICATIONS
9.5.1. Overview
9.5.2. Other Applications Market Forecast and Analysis
10. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS & CLINICS
10.3.1. Overview
10.3.2. Hospitals & Clinics Market Forecast and Analysis
10.4. LABORATORIES
10.4.1. Overview
10.4.2. Laboratories Market Forecast and Analysis
11. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.1.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.1.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.1.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.1.5 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.1.6 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.1.7 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.1.7.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.1.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.1.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.1.3 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.1.4 United States Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.2.1 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.2.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.2.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.2.4 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.3.1 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.3.2 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.3.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2. EUROPE
11.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.2.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.2.5 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.2.6 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.2.7 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.1.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.1.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.1.3 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.1.4 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.2 France Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.2.1 France Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.2.2 France Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.2.3 France Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.2.4 France Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.3.1 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.3.2 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.3.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.3.4 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.4.1 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.4.2 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.4.3 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.4.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.5 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.5.1 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.5.2 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.5.3 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.5.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.3.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.3.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.3.6 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.1.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.1.2 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.1.3 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.1.4 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.2 China Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.2.1 China Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.2.2 China Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.2.3 China Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.2.4 China Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.3 India Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.3.1 India Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.3.2 India Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.3.3 India Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.3.4 India Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.4.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.4.2 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.4.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.4.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.5 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.5.1 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.5.2 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.5.3 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.5.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.4.2 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.4.3 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.4.4 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.4.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.4.6 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.1.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.1.2 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.1.3 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.1.4 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.2.1 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.2.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.2.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.2.4 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.3.1 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.3.2 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.3.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.3.4 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.5.2 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.5.3 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.5.4 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.5.5 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.5.6 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.5.7 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.1.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.1.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.1.3 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.1.4 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.2.1 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.2.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.2.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.2.4 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET, KEY COMPANY PROFILES
13.1. AGILENT TECHNOLOGIES, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CARIS LIFE SCIENCES
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. F. HOFFMANN-LA ROCHE LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. FOUNDATION MEDICINE, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ILLUMINA, INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MYRIAD GENETICS, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. OXFORD NANOPORE TECHNOLOGIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PARADIGM DIAGNOSTICS, INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. QIAGEN
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERMO FISHER SCIENTIFIC INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Clinical Oncology Next Generation Sequencing (NGS) Market - By Technology
1.3.2 Clinical Oncology Next Generation Sequencing (NGS) Market - By Workflow
1.3.3 Clinical Oncology Next Generation Sequencing (NGS) Market - By Application
1.3.4 Clinical Oncology Next Generation Sequencing (NGS) Market - By End User
1.3.5 Clinical Oncology Next Generation Sequencing (NGS) Market - By Region
1.3.5.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - GLOBAL MARKET ANALYSIS
6.1. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET OVERVIEW
6.2. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - TECHNOLOGY
7.1. OVERVIEW
7.2. TECHNOLOGY MARKET FORECASTS AND ANALYSIS
7.3. WHOLE EXOME SEQUENCING
7.3.1. Overview
7.3.2. Whole Exome Sequencing Market Forecast and Analysis
7.4. WHOLE GENOME SEQUENCING
7.4.1. Overview
7.4.2. Whole Genome Sequencing Market Forecast and Analysis
7.5. TARGETED SEQUENCING & RESEQUENCING
7.5.1. Overview
7.5.2. Targeted Sequencing & Resequencing Market Forecast and Analysis
8. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - WORKFLOW
8.1. OVERVIEW
8.2. WORKFLOW MARKET FORECASTS AND ANALYSIS
8.3. NGS DATA ANALYSIS
8.3.1. Overview
8.3.2. NGS Data Analysis Market Forecast and Analysis
8.4. NGS PRE-SEQUENCING
8.4.1. Overview
8.4.2. NGS Pre-Sequencing Market Forecast and Analysis
8.5. NGS SEQUENCING
8.5.1. Overview
8.5.2. NGS Sequencing Market Forecast and Analysis
9. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
9.1. OVERVIEW
9.2. APPLICATION MARKET FORECASTS AND ANALYSIS
9.3. COMPANION DIAGNOSTICS
9.3.1. Overview
9.3.2. Companion Diagnostics Market Forecast and Analysis
9.4. SCREENING
9.4.1. Overview
9.4.2. Screening Market Forecast and Analysis
9.4.3. Inherited Cancer Market
9.4.3.1. Overview
9.4.3.2. Inherited Cancer Market Forecast and Analysis
9.4.4. Sporadic Cancer Market
9.4.4.1. Overview
9.4.4.2. Sporadic Cancer Market Forecast and Analysis
9.5. OTHER APPLICATIONS
9.5.1. Overview
9.5.2. Other Applications Market Forecast and Analysis
10. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET - REVENUE AND FORECASTS TO 2027 - END USER
10.1. OVERVIEW
10.2. END USER MARKET FORECASTS AND ANALYSIS
10.3. HOSPITALS & CLINICS
10.3.1. Overview
10.3.2. Hospitals & Clinics Market Forecast and Analysis
10.4. LABORATORIES
10.4.1. Overview
10.4.2. Laboratories Market Forecast and Analysis
11. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
11.1. NORTH AMERICA
11.1.1 North America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.1.2 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.1.3 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.1.4 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.1.5 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.1.6 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.1.7 North America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.1.7.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.1.1 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.1.2 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.1.3 United States Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.1.4 United States Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.2.1 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.2.2 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.2.3 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.2.4 Canada Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.1.7.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market
11.1.7.3.1 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.1.7.3.2 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.1.7.3.3 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.1.7.3.4 Mexico Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2. EUROPE
11.2.1 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.2.2 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.2.3 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.2.4 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.2.5 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.2.6 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.2.7 Europe Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.2.7.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.1.1 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.1.2 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.1.3 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.1.4 Germany Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.2 France Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.2.1 France Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.2.2 France Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.2.3 France Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.2.4 France Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.3.1 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.3.2 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.3.3 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.3.4 Italy Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.4.1 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.4.2 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.4.3 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.4.4 Spain Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.2.7.5 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market
11.2.7.5.1 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.2.7.5.2 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.2.7.5.3 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.2.7.5.4 United Kingdom Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3. ASIA-PACIFIC
11.3.1 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.3.2 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.3.3 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.3.4 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.3.5 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.3.6 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.3.7 Asia-Pacific Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.3.7.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.1.1 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.1.2 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.1.3 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.1.4 Australia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.2 China Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.2.1 China Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.2.2 China Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.2.3 China Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.2.4 China Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.3 India Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.3.1 India Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.3.2 India Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.3.3 India Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.3.4 India Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.4.1 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.4.2 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.4.3 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.4.4 Japan Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.3.7.5 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market
11.3.7.5.1 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.3.7.5.2 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.3.7.5.3 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.3.7.5.4 South Korea Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4. MIDDLE EAST AND AFRICA
11.4.1 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.4.2 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.4.3 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.4.4 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.4.5 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.4.6 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.4.7 Middle East and Africa Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.4.7.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.1.1 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.1.2 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.1.3 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.1.4 South Africa Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.2.1 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.2.2 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.2.3 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.2.4 Saudi Arabia Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.4.7.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market
11.4.7.3.1 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.4.7.3.2 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.4.7.3.3 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.4.7.3.4 U.A.E Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5. SOUTH AND CENTRAL AMERICA
11.5.1 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Overview
11.5.2 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis
11.5.3 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Technology
11.5.4 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Workflow
11.5.5 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Application
11.5.6 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By End User
11.5.7 South and Central America Clinical Oncology Next Generation Sequencing (NGS) Market Forecasts and Analysis - By Countries
11.5.7.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.1.1 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.1.2 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.1.3 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.1.4 Brazil Clinical Oncology Next Generation Sequencing (NGS) Market by End User
11.5.7.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market
11.5.7.2.1 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Technology
11.5.7.2.2 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Workflow
11.5.7.2.3 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by Application
11.5.7.2.4 Argentina Clinical Oncology Next Generation Sequencing (NGS) Market by End User
12. INDUSTRY LANDSCAPE
12.1. MERGERS AND ACQUISITIONS
12.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
12.3. NEW PRODUCT LAUNCHES
12.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
13. CLINICAL ONCOLOGY NEXT GENERATION SEQUENCING (NGS) MARKET, KEY COMPANY PROFILES
13.1. AGILENT TECHNOLOGIES, INC.
13.1.1. Key Facts
13.1.2. Business Description
13.1.3. Products and Services
13.1.4. Financial Overview
13.1.5. SWOT Analysis
13.1.6. Key Developments
13.2. CARIS LIFE SCIENCES
13.2.1. Key Facts
13.2.2. Business Description
13.2.3. Products and Services
13.2.4. Financial Overview
13.2.5. SWOT Analysis
13.2.6. Key Developments
13.3. F. HOFFMANN-LA ROCHE LTD
13.3.1. Key Facts
13.3.2. Business Description
13.3.3. Products and Services
13.3.4. Financial Overview
13.3.5. SWOT Analysis
13.3.6. Key Developments
13.4. FOUNDATION MEDICINE, INC.
13.4.1. Key Facts
13.4.2. Business Description
13.4.3. Products and Services
13.4.4. Financial Overview
13.4.5. SWOT Analysis
13.4.6. Key Developments
13.5. ILLUMINA, INC.
13.5.1. Key Facts
13.5.2. Business Description
13.5.3. Products and Services
13.5.4. Financial Overview
13.5.5. SWOT Analysis
13.5.6. Key Developments
13.6. MYRIAD GENETICS, INC.
13.6.1. Key Facts
13.6.2. Business Description
13.6.3. Products and Services
13.6.4. Financial Overview
13.6.5. SWOT Analysis
13.6.6. Key Developments
13.7. OXFORD NANOPORE TECHNOLOGIES
13.7.1. Key Facts
13.7.2. Business Description
13.7.3. Products and Services
13.7.4. Financial Overview
13.7.5. SWOT Analysis
13.7.6. Key Developments
13.8. PARADIGM DIAGNOSTICS, INC.
13.8.1. Key Facts
13.8.2. Business Description
13.8.3. Products and Services
13.8.4. Financial Overview
13.8.5. SWOT Analysis
13.8.6. Key Developments
13.9. QIAGEN
13.9.1. Key Facts
13.9.2. Business Description
13.9.3. Products and Services
13.9.4. Financial Overview
13.9.5. SWOT Analysis
13.9.6. Key Developments
13.10. THERMO FISHER SCIENTIFIC INC.
13.10.1. Key Facts
13.10.2. Business Description
13.10.3. Products and Services
13.10.4. Financial Overview
13.10.5. SWOT Analysis
13.10.6. Key Developments
14. APPENDIX
14.1. ABOUT THE INSIGHT PARTNERS
14.2. GLOSSARY OF TERMS
The List of Companies
1. Agilent Technologies, Inc.
2. Caris Life Sciences
3. F. Hoffmann-La Roche Ltd
4. FOUNDATION MEDICINE, INC.
5. Illumina, Inc.
6. Myriad Genetics, Inc.
7. Oxford Nanopore Technologies
8. Paradigm Diagnostics, Inc.
9. QIAGEN
10. Thermo Fisher Scientific Inc.
1. Agilent Technologies, Inc.
2. Caris Life Sciences
3. F. Hoffmann-La Roche Ltd
4. FOUNDATION MEDICINE, INC.
5. Illumina, Inc.
6. Myriad Genetics, Inc.
7. Oxford Nanopore Technologies
8. Paradigm Diagnostics, Inc.
9. QIAGEN
10. Thermo Fisher Scientific Inc.